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ABSTRACT

THE EFFECT OF A NEW HOSPITAL-BASED
CONGESTIVE HEART FAILURE CARE PROTOCOL
ON RATE OF 30-DAY READMISSION AMONG CHF PATIENTS
FEBRUARY 2015
ERIC A. COHEN
B.A., SWARTHMORE COLLEGE
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Penelope Pekow

Approximately 20% of congestive heart failure (CHF) patients are readmitted within 30
days of hospital discharge, a rate which may be affected by in-hospital and post-discharge
care. Reducing this rate is important to hospitals, both to improve outcomes and to avoid
reductions in Medicare reimbursement. Assessing outcomes within a short post-discharge
window best measures the impact of the care, planning, and followup of that admission;
but most research on the effects of changes in CHF care has measured outcomes over
periods longer than 30 days, adding the unpredictable long-term course of CHF to the
factors affecting the outcome. As well, almost no studies to date have included the
appreciable effects of CHF comorbidities in their analyses.
This study addresses these needs by measuring rates of 30-day all-cause readmission, and
by adjusting for comorbidities and demographic factors in our analysis.
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We hypothesize that an improved CHF care protocol including both in-hospital and postdischarge components will reduce the risk of readmission, and may alter the rate of
change of that risk.
We have analyzed as an interrupted time series data on 2764 discharges of CHF patients
from a hospital that implemented such a change to assess the effect of the new protocol
on the readmission risk and on the trend in that risk, comparing outcomes in the 22
months preceding introduction of the new protocol to those in the first 31 months of full
implementation. Using multiple logistic regression, we have tested for an association
between the new protocol and both the unadjusted risk of readmission, and that risk in a
model including comorbidities and demographic factors as covariates.
Neither model found a statistically significant association between introduction of the
protocol and log-odds of readmission (unadjusted p = 0.847, adjusted p = 0.755) or
between introduction of the protocol and change in risk of readmission over time
(unadjusted p = 0.437, adjusted p = 0.313).
These results, in comparison with other published results, can clarify what changes to
care protocols have been shown to be effective. Further, post hoc power analysis of this
study can inform study design for further research.
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CHAPTER 1
INTRODUCTION
Congestive heart failure (CHF) is a substantial health burden in the United States. In
2012 prevalence in U.S. adults was 2.4% (1), annual incidence in developed countries is
estimated at 5 to 10 per 100,000 (2), and a U.S. resident’s lifetime risk for CHF is one in
five (3). Outcomes are poor as well: one-year mortality ranges from 7% for cases of mild
CHF to 28% for cases of severe CHF (4), and among Medicare beneficiaries hospitalized
for CHF, half will not survive three years (1). Secondary to the human cost, CHF imposes
a substantial economic burden: Healthcare spending on CHF is 1% to 2% of total
worldwide healthcare spending (2), and the indirect economic loss — due to mortality
and morbidity — has been estimated at over nine billion dollars in the U.S. in 2012 (1).
Readmission is a major feature of both poor patient outcomes and healthcare cost. A
patient hospitalized for CHF will often be quickly readmitted for the same or a related
complaint — the average 15-day readmission rate for CHF is 12.5% (5). Wide
differences in outcome show that a high readmission rate is not inevitable: adjusted for
severity, 15% of US hospitals have CHF readmission rates 5% or more higher than
expected, and 5% have rates 5% or more lower (5). This suggests that the issue is
amenable to public health intervention: certain practices can reduce the risk of CHF
readmission. Recent healthcare policy has also affected this concern, as the Affordable
Care Act of 2010 provides for escalating penalties for hospitals that do not reduce
readmissions categorized as unnecessary readmissions (6). Identifying measures that
reduce CHF patient readmission, particularly readmission within 30 days of discharge, is
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therefore central to both improving patient outcomes and to allowing hospitals to avoid
financial penalties.
Studies have shown that improved care protocols reduce readmissions. Interventions
including patient education, telephone followup, medication management, and
coordinated transitional care have been shown in various studies to reduce readmissions
in Medicare patients with coronary artery disease, congestive heart failure, diabetes,
chronic pulmonary disease, or some combination of those conditions (7). Medication
reconciliation and scheduling followup appointments prior to discharge have been shown
to reduce readmission in CHF patients (8).
However, although many CHF care protocols have been studied, all improved protocols
have included primarily post-discharge interventions and few in-hospital interventions.
But for a hospital attempting to improve care, or avoid reimbursement penalties, inhospital care may be the preferred focus of effort. Changes to in-hospital procedures can
be implemented more quickly and easily than changes requiring coördination with
external agencies or care providers. As well, the costs and reimbursability of in-house
care practices are more readily forecast.
As well, despite the many studies, little information is available focusing particularly on
30-day readmission; all previous studies concentrate on longer-term outcomes of interest.
Although the long-term course of CHF progression is of real importance to assessing
patient care, we believe that the unpredictability of this course, dependent as it is on the
complex interaction of many comorbidities, life events, and the choices of patients and
caregivers, decreases the utility of longer-term measures in assessing the quality of a
given hospital admission.
2

Finally, although comorbidities are significant predictors of readmission risk in CHF
patients (9), little of the available literature adjusts for these covariates.
Addressing these deficits, we have studied the effects on 30-day all-cause readmission of
a CHF care protocol introduced by Baystate Medical Center in January 2009. This new
protocol was centered on in-hospital changes to care. The available data includes
demographic information and information on comorbidities at discharge, allowing us to
adjust for these effects when testing the study hypotheses.

Epidemiology of CHF care protocols and risk of readmission
Multiple studies have investigated the association between improved CHF care protocols
and risk of readmission in CHF patients.
Restricting ourselves to studies conducted since 2000, and concentrating on studies
addressing (at least tangentially) measures similar to our outcome of interest, the studies
surveyed have all been randomized controlled trials (RCTs) and have almost uniformly
found a reduction in the risk of all-cause readmission for CHF patients receiving care
under an improved protocol, relative to those receiving the standard of care (10–17). Of
the eight studies surveyed, six found an improvement in this outcome (11,12,14,16–18),
one found a statistically insignificant improvement (at 95% confidence) (15), and only
one found no association between the new protocol and lower risk of all-cause
readmission (10). Meta-analyses are common in this area, and of seven meta-analyses
surveyed (all addressed only RCTs), six found an overall tendency towards lowered rates
of all-cause readmission in patients treated under an improved care protocol relative to
the standard of care (19–25), and only one found no association (26).
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Of the studies surveyed, the COACH study described by Jaarsma et al. is notable for
being by far the largest trial surveyed (1,023 patients) and for finding no association
between the intervention and any of its outcomes (10). This 2003–2005 RCT was
conducted across 17 hospitals in the Netherlands. Patient inclusion criteria included
hospital admission for CHF and age ≥ 18 years (27). Patients were randomized to one of
three exposure groups: The control group (n = 339) received standard care. A “Basic
Support Group” (n = 340) received in-hospital education, nine additional post-discharge
clinic visits with a CHF nurse, and post-discharge education and strategies for adherence
to medical advice. An “Intensive Support Group” (n = 344) received the above, but with
18 clinic visits with a CHF nurse, two CHF nurse home visits, two multidisciplinary
consultation sessions, and telephone followup from a CHF nurse.
The study followed patients for 18 months. Analysis of time to first event of either CHF
hospitalization or death showed a hazard ratio of 0.96 (95% confidence interval (CI) 0.76
– 1.21, p = 0.73) for patients in the basic support group relative to patients receiving
standard care, and 0.93 (95% CI 0.73 – 1.17, p = 0.53) for patients in the intensive
support group relative to patients receiving standard care — that is, no significant effect
of the interventions. Some information on our outcome of interest, all-cause readmission,
is available from this study but not over a span of 30 days. Over their 18-month
surveillance period, the study found an incidence rate ratio of 1.07 (95% CI 0.83 – 1.37, p
= 0.62) for readmissions (counting multiple admissions per patient) for the combined
intervention groups versus the control group. Jaarsma et al. have proposed that the null
results may be due to the high standard of care in the control group: an average of over
five cardiologist followup visits per control-group patient in the 18-month period, a high
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standard of GP care in the Netherlands, and high patient compliance even in the control
group (28).
The study most similar to our own is that of Anderson et al (18). Results of this study
include rate of all-cause 30-day readmission, and the intervention included some inhospital components, making it particularly relevant to our concerns. (Both of these
features are rare in the literature surveyed). The study was also unusual in at least
partially addressing the issue of comorbidities: number of patient comorbidities was
assessed at study intake, and although the nature of the comorbidities was not considered
and the number of comorbidities was not a factor in the analysis, the two groups were not
statistically significantly different on this measure. This study was an RCT enrolling
patients with primary diagnosis of CHF admitted to Bridgeport Hospital, Bridgeport, CT,
between January 1, 1996 and March 31, 1997. Total population was 121 patients (77
control, 44 intervention). The in-patient portions of the intervention included a one-hour
consultation with a cardiac nurse specialist; half-hour consultations with each of a
physical therapist and a dietician; and discharge planning by a cardiac nurse specialist,
coordinated with home health nurses who would be providing post-discharge care. The
post-discharge intervention included a followup phone evaluation with a nurse case
manager, and 6–20 visits (depending on patient progress) by a home health nurse.
Patients were followed for six months.
The study found the intervention to be effective: patients in the intervention group had an
11.4% rate of all-cause six-month readmission compared with a 44.2% readmission rate
for patients in the control group (p = 0.01, risk ratio and confidence intervals not

5

reported). For our outcome of interest, the rate of all-cause 30-day readmission was 6.0%
in the intervention group versus 22.1% in the control group (p = 0.01).
Despite the randomized design, estimates in this study may have been affected by
imbalance in some covariates. Of patients in the intervention group, 13% were married
and 50% lived alone; by comparison, of those in the control group, 35% were married (p
= 0.09) and 27% lived alone (p = 0.01). The support of a companion at home in activities
of daily living will have an appreciable effect on health outcomes in a frail or elderly
population such as this. Patients receiving the intervention were thus in more difficult
circumstances than those not — this would bias Anderson’s results towards the null, and
the effects of the intervention may, in fact, be stronger than shown in this study.
Overall, the existing literature finds a positive association between care under an
improved CHF care protocol incorporating primarily post-discharge interventions, and
reduced risk of readmission for CHF patients.

Motivation
CHF, and readmission of CHF patients within 30 days of discharge, are substantial health
burdens in the United States. Reducing the rate of CHF readmission will help to better
utilize healthcare resources and improve patient outcomes. Studies generally show that
improved care protocols reduce the risk of readmission, but the existing studies do not
provide adequate information for U.S. hospitals considering changes to CHF care.
First, changes to the in-hospital portions of care are those most readily implemented by a
hospital, but little information is available on interventions based primarily on in-hospital
interventions. Of the eight protocols surveyed, six mandated post-discharge home visits
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(10,12,14,15,17,18), one included a possible physician home visit (11), and one included
nurse home visits if clinic visits were impractical (16). These are protocols that may be
more difficult for a hospital to implement, as they may involve non-reimbursed medical
or nursing activities, and coordination with external private or governmental
organizations. Only two studies of those surveyed (14,18) included any in-hospital
interventions. The issue of home visits may be particularly problematic, as two metaanalyses found that in-person communication was effective whereas telephonic
communication was ineffective (19) or of borderline significance (22); whereas in-person
communication can be harder for a hospital to implement or find reimbursement for.
(One meta-analysis (20) found in-person and telephone communication to be equally
effective.)
Second, the outcomes of interest in the studies surveyed are very diverse, but none has a
30-day outcome as a primary outcome of interest; followup periods in the surveyed
studies range from 60 days to two years. A short followup window, unlike those in the
studies surveyed, provides a measure of proximate care quality that is not affected by the
unpredictable long-term course of CHF and its frequent comorbidities. The 30-day
measure allows more focused information on the index admission: quality of care,
medical stability at discharge, and quality of discharge planning. A 30-day measure is
also consistent with the other readmission measures tracked by the National Quality
Forum, and with data available from the Centers for Medicare and Medicaid Services.
Finally, only one (12) of the eight studies surveyed adjusted the analysis for patient
comorbidities. It seems intuitive that a 90-year-old patient with diabetes and chronic
kidney disease should be at greater risk of readmission than a 65-year-old with no
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comorbidities; and that a model that compares one to the other without allowing for these
unequal risks may be inaccurate. In fact, comorbidities are common and do affect risk of
readmission: Dahlström (29) found anemia in over 20% of CHF patients; Havranek et
al.(30) found that over 30% of CHF patients also had COPD, 40% had diabetes, and more
than 50% had each of coronary heart disease and a history of hypertension. These and
other comorbidities appreciably affect risk of readmission, as shown by Silverstein et al.
(9) and Philbin and DiSalvo (31).
It may be argued that the RCT nature of the existing studies obviates the need for
including covariates in their analyses, but there is substantial potential for residual
confounding. Particularly for studies with small sample size, stating that two study
groups did not significantly differ along some factor is a weaker analysis than controlling
or adjusting for that factor. Of the studies surveyed, the median sample size was 173
divided among two or more groups, and excluding Jaarsma et al. (which found no effect
and had N = 1,023) the maximum was 239. By contrast, our study covers 2,764
discharges. None of the studies surveyed controlled for covariates by blocking
randomization along any dimension other than study site.
Therefore, we have studied the effect of a primarily hospital-based intervention, through
the intervention’s effects on all-cause 30-day readmission rates, with adjustment for
patient demographics and comorbidities present during the admission. We believe this
has provided more salient and more accurate information for healthcare planners
considering changes to CHF care.
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Specific aims and hypotheses
Specific aim: To evaluate the effect of a new CHF care protocol on the risk of all-cause
30-day readmission for patients discharged with a diagnosis of CHF from Baystate
Medical Center from September 2007 through July 2012.
Hypothesis 1: The implementation phase of the new protocol will be associated with a
lower adjusted risk of all-cause 30-day readmission in CHF patients than would be
expected on the basis of the baseline risk and secular trend in risk of readmission during
the pre-implementation phase.
Hypothesis 2: The implementation phase of the new protocol will be associated with a
trend in the adjusted risk of all-cause 30-day readmission in CHF patients that is not
equal to the trend in the adjusted risk during the pre-implementation phase.
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CHAPTER 2
METHODS

Study design
This trial assessed the association between care under a new protocol for CHF care, and
risk of all-cause hospital re-admission within 30 days of discharge, among CHF patients
at Baystate Medical Center, in Springfield, MA.
In July 2009, Baystate Medical Center began implementation of a new protocol for care
of CHF patients. This change provided an opportunity for a natural experiment to assess
the effect of treatment under this new protocol. We compared the risk of all-cause 30-day
readmission in the period following the introduction of the new protocol (the
implementation phase) to the risk in the period preceding the introduction of the new
protocol (the pre-implementation phase).
Information on discharge diagnoses and on readmissions was collected for a period of 59
months beginning in September, 2007, and extending through and after the
implementation of the new protocol (Figure 1).
Ramp-up
phase

Pre-implementation phase

^

September 2007
Data collection begins

^

July 2009
Protocol first
introduced

Implementation phase

^

January 2010
Protocol fully in
place

^

July 2012
Data collection ends

Figure 1: Data-gathering and exposure timeline for implementation of the new CHF care
protocol at Baystate Medical Center.
Each datapoint consists of a hospital discharge during this period, including month and
year of discharge; medical and demographic information on the patient at the time of
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discharge; and whether the patient was readmitted for any cause within 30 days of that
discharge.
We have not included data from the ramp-up period in our analysis, a decision made prior
to analysis. We believed that any conclusions regarding this relatively brief span (327 of
3091 total discharges, over six months) would have too large a variance to be useful,
particularly regarding trend over time; and that amalgamating this data with that from
either the preceding or succeeding phases would only bias any results towards the null.
Study population
Baystate Medical Center is a tertiary care hospital serving an ethnically and
socioeconomically diverse population in Springfield, MA, a city of 150,000 in western
Massachusetts. Participants in this study received care on the dedicated CHF care ward in
Baystate Medical Center’s main hospital building on its main campus.
The study covered all patients aged 18 or older discharged alive from the dedicated CHF
care ward, with a primary discharge diagnosis of CHF, during the study periods of
September 2007 – July 2009 (the pre-implementation phase) and January 2010 – July
2012 (the implementation phase), whose discharge did not occur within 30 days of a prior
Baystate Medical Center discharge (i.e., whose admission was not a readmission from an
admission included in the study). CHF patients admitted to other wards (as, possibly, if
the CHF ward was full), and patients discharged from the CHF ward with a primary
discharge diagnosis other than CHF, were not included in the source population.
Researchers determined patient hospitalization dates and discharge diagnoses (based on
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ICD-9 codes) through administrative data provided from Baystate Medical Center’s
McKesson financial decision support system (see APPENDIX for ICD-9 codes used).
Exposure
The exposure of interest was care under the new CHF care protocol. This protocol
included changes from the prior standard of care both in-hospital and post-discharge. Inhospital, under the new protocol, CHF patients are screened on admission to identify
those at high risk of readmission. CHF patients are geographically centralized on a single
ward, a policy already in place as the preceding standard of care, but the new protocol
instituted supervision of CHF patient cases by a dedicated CHF nurse manager,
coordinated multi-disciplinary rounds for CHF patients, as well as monthly multidisciplinary meetings aimed at CHF care. While in hospital, CHF patients are given a
detailed medication reconciliation, specialized patient education, and each patient’s first
followup appointment is scheduled prior to discharge. Following discharge, patients are
followed by phone.
Care under the reference condition — during the pre-implementation phase — was
Baystate Medical Center’s standard of care for CHF patients in place at that time.
Exposure was assessed by comparing a subject’s discharge date with the dates defining
the pre-implementation and implementation phases. Exposure for each discharge was
measured as a single dichotomous variable (Table 1).
Outcome
The outcome of interest was readmission to a hospital, for any reason, within 30 days of
the index discharge from Baystate Medical Center. The outcome for each discharge was
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measured as a single dichotomous variable (Table 1). The possibility of inaccuracy
through admission to a facility other than Baystate is addressed in Study limitations,
below.
The validity of inclusion, exposure, and outcome assessment depend largely on the
accuracy and completeness of hospital administrative records. We believe the hospital
administrative records to be highly complete and accurate for our required information —
admission and discharge dates, accurate matching on unique patient ID, and admission
diagnosis — due to the hospital’s need for these records for legal compliance, liability
limitation, reimbursement, and census tracking.
Covariates
Potential predictors of readmission risk were chosen from those in the hospital
administrative data based on covariates used in previous studies of CHF readmission (10–
12,14,15,17,18). We chose age, gender, race/ethnicity, source of payment for medical
costs, primary diagnosis, secondary diagnoses, length of hospital stay, and discharge
disposition (such as home with self care, home with visiting nurse assistance, skilled
nursing facility, etc.) as potential predictors of readmission risk in multivariable modelbuilding.
Information on the covariates was gathered from the administrative records mentioned
above. Covariates are coded as described in Table 1.

Interrupted time-series analysis
Interrupted time-series analysis is a quasi-experimental protocol that allows comparison
of a series of outcome values before and after some change in conditions — the
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“interruption”. For instance, a study could examine the daily number of emergency-

outcome

department visits for asthma, before and after a ban on smoking in public places.

time

interruption

Rather than simply comparing mean values before and after the interruption, this type of
analysis can account for a secular trend in the outcome over time. (If rates of asthma
admission were declining independent of the smoking ban, then a lower rate of admission
after the ban should not, alone, be used to indicate an effect of the ban.) As well, it can
detect a change in trend associated with the interruption. (Perhaps, with lower asthma
admission rates after the smoking ban, the secular trend towards lower rates was reduced

outcome

given the smaller room for improvement.)

change in
slope

change in
baseline

time

interruption
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As a regression model, this is expressed as
 



 

  

 

Equation 1
where

 is the secular trend over time;  is an indicator variable indicating

before/after the interruption, so that   is the change in baseline after the interruption;
and  is the change in trend after the interruption.
As the outcome in this study is a binary outcome, we tested regression models of the
form
 



 

  

 

Equation 2
The questions of interest were whether   0 (whether there was a change in baseline
log-odds of readmission), and whether   0 (whether there was a change in the trend of
log-odds of readmission); in particular, we hypothesized that   0.
Protocol implementation had, in fact, two interruptions — start of the ramp-up period for
implementation of the protocol, and full implementation of the protocol (Figure 1). As we
did not incorporate data from the ramp-up period, this was appropriately modelled with a
single interruption. Omitting this data also means that the date for defining before/after
the interruption, that is, the time after which the indicator   1, can be defined as any
time within the ramp-up period without affecting the model.
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We tested both a raw model, incorporating only the predictors time, i, and time i, and the
best logistic regression model that we arrived at incorporating those as well as medical
and demographic covariates.

Time-series analysis
The regression analysis described requires that the outcomes be independent, whereas
time-based measurements often do not to meet this assumption. Time-based outcomes
can be autocorrelated: the expected value for the outcome at one time can depend on the
observed values at previous times. (The expected closing price of the Dow Jones index
for one day is not independent of the observed closing price the previous day.) When
autocorrelation is present, analysis via an ARIMA model rather than simple regression is
required. Time-based outcomes often also exhibit cyclical behavior: hospital admissions
for influenza exhibit a regular seasonal pattern. We examined correlograms of the
probabilities of readmission, amalgamated both monthly and quarterly, to detect
autocorrelation and seasonality.

Logistic regression model
Covariates
The candidate covariates available for logistic regression models of risk of readmission
were:
 age
 sex
 race/ethnicity (white, black, Hispanic, other/unknown);
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 medical cost payor (commercial medical insurance/HMO, Medicaid, Medicare, other)
 discharge disposition (against medical advice; home to self-care; home with visiting
nurse assistance; hospice; rehabilitation or other skilled nursing facility; transfer)
 length of hospital stay
 primary diagnosis
 secondary diagnoses
Primary diagnosis was expressed as an ICD-9 code. To address cell sparsity, we
condensed these diagnoses from the ICD-9 four-digit subcategories and five-digit
subdivisions into their three-digit ICD-9 categories (so, for instance, “428.21 Acute
systolic heart failure” and “428.9 Heart failure, unspecified” both mapped to “428 Heart
failure”). The resulting categories were coded as indicator variables and used for
regression.
We hypothesized that length of stay might have a nonmonotonic relation with outcome,
so we binned length of stay into short, medium, and long, and built separate regression
models treating length of stay as either continuous or categorical. The bin cutpoints were
determined upon examining the distribution of length of stay in our data, but prior to any
data analysis.
Gagne score
Patient comorbidities are important risk factor for readmissions, and information on these
is available for this study from the set of secondary diagnoses for the patient at discharge.
These are coded as ICD-9 diagnosis codes. In our data, each discharge is associated with

17

from 0 to 48 distinct secondary diagnoses, and 1930 secondary diagnoses are represented.
Cell sparsity forbids treating these as distinct predictors, so some binning or summary
measure is called for.
We elected to summarize the information from the secondary diagnoses using the Gagne
comorbidity score (33). Developed to predict 30-day mortality in an elderly population,
this has been shown to have better predictive value (33) in this population than summary
scores based on the Elixhauser comorbidity classification system (34) or the Charlson
Index (35), and was favorably reviewed in a comparison of scoring systems for predicting
mortality in the elderly (36). We did not elect to use the risk score developed by Philbin
et al. specifically for prediction of hospital readmission for heart failure (31) as this
measure incorporates several measures that are included as separate covariates in our
model (race/ethnicity, medical charge payor, discharge disposition) and requires patient
medical information not available in our data. Although our interest is morbidity rather
than mortality, the study population is elderly (Table 4), as is that in the data used to
create the Gagne score, and we believe the Gagne score to be an appropriate candidate
covariate for adjusting risk of readmission in our logistic regression model.
Model-building
For models that did not include any covariates, we determined to test three unadjusted
logistic regression models:
1. predictors time, i, and time i;
2. i only (test for change in baseline);
3. time only (test for secular trend).
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Time was included as month of study, centered on the beginning of the intervention
phase (time = month of study – 28). We centered the time variable to reduce the artificial
collinearity between time and time i.
For a regression model including covariates, we first built a model including:
i.

predictors time, i, and time i;

ii.

predictors age and sex, which we had determined to include in all models;

iii.

candidate predictors primary diagnosis (condensed to 3-digit ICD-9 categories),
race/ethnicity, medical charge payor, discharge disposition, Gagne score, and
length of hospital stay.

We then built a new model including the predictors from i) and ii) above, and only the
predictors from iii) that showed p values ≤ 0.25 by the Wald significance test. We
examined the remaining predictors from iii) for collinearity with the predictors of
interest, time and i. If collinearity was satisfactory and all remaining predictors had Wald
significance p ≤ 0.25, we chose this as the regression model to test. We did not continue
eliminating predictors to arrive at the most parsimonious model, as our goal was to adjust
for confounding factors rather than to arrive at a predictive model or investigate which
variables might be most strongly associated with the outcome.
We repeated the above procedure including length of stay, categorized as described
above, in place of length of stay as a continuous variable, in the model-building.
We repeated the above procedure replacing the predictors in i) above with i only (test for
change in baseline) and time only (test for secular trend).
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Model evaluation
Model significance
We used a likelihood-ratio test, comparing each model to the naïve (intercept-only)
model, to test the evidence for rejecting the null hypothesis that the given model was no
better than the naïve model.
Goodness of fit
We evaluated the goodness of model fit, for regression models of interest, via the
Hosmer-Lemeshow test. Due to the sensitivity of this test to the choice of cutpoints (37)
(38), we evaluated the test for several numbers of groups, and supplemented those results
with the result from the le Cessie-van Houwelingen-Copas-Hosmer unweighted sum of
squares test statistic ( ! in (37), USS in (38)).
We also evaluated the unadjusted regression model — the model including only
predictors time, i, and time i — via its Pearson residuals. The discharge dates provided
in the source data are quantized by month (year and month of discharge are reported, but
not date). For the model including only predictors time, i, and time i, then, it is
meaningful to group the model results by covariate patterns, which results in one distinct
pattern for each month of the study, and compare the observed number of readmissions in
each month with that predicted by the model. (The relativity small number of covariate
patterns — 53 study months — and high number of events — several dozen discharges
per month — avoid the issue of cell sparsity in this analysis.) We also evaluated the
normality of the Pearson residuals in this model.
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Finally, we investigated the appropriateness of the unadjusted regression model by
examining a plot of the outcome (risk of readmission, aggregated by month) as a function
of the only continuous predictor, time, for any patterned deviation from linearity which
would suggest that a transform of the data might be in order prior to analysis.

Statistical power
We conducted a post hoc power analysis of the study to test what effect size could be
detected, in a population similar to this in a study of this type. We tested this via
simulation, for an array of effect sizes, to determine the study’s power at each effect size.
The procedure, for a single effect size, was:
1. Referring to the best regression model arrived at above,
 



 

  

 

choose a value for γ (the change in baseline) and a value for ρ (the change in trend).
This is the effect size that will be simulated.
2. Simulate a set of data points that is of the same size as the actual study dataset, and as
similar as possible to the study data, calculating the outcome for each data point via the
regression model:



The coefficients γ and ρ have been chosen above;
, , and the coefficients for any other predictors can be set at their best-fit
estimates from the regression model being used;
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from those values, and from the covariate values for that data point, calculate a
value of p for that datapoint. Set the outcome for that datapoint to true
(readmission) with probability p.

Applied to all datapoints in the simulated data set, this produces a set of simulated data
whose outcomes are those that would be expected if there truly were a change in
baseline of size  and a change in trend of size  in the process underlying the
outcomes for population being sampled.
3. Fit a logistic regression model to this simulated dataset. Test: does this model
(correctly) reject the null hypothesis that   0 with statistical significance of 95%?
Does this model (correctly) reject the null hypothesis that   0 with statistical
significance of 95%?
4. Repeat steps 2 and 3 for 500 repetitions, to calculate the proportion of times that this
procedure correctly rejects each null hypothesis for the given effect size — that is, for
each hypothesis calculate the power of the study.
We repeated this procedure for an array of values of γ and ρ to determine the power of the
study at a variety of effect sizes.
Step 2, simulating a set of datapoints, involved some decisions. The true dataset, in
addition to summary properties — 50% male, median age 76, and so on — has a complex
covariance structure: for instance, age is not independent of sex. This structure should be
preserved in simulated data that is intended to represent samples from a similar
population. Therefore, we decided to simulate data via bootstrapping: each simulated
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datapoint is an element drawn from the set of actual datapoints, with replacement. (The
outcome for each datapoint is calculated as described above).
When calculating the datapoint outcomes for a given effect size, we also adjusted β0, the
intercept, to maintain an overall risk of readmission over the entire sample close to that in
the actual dataset. Increasing or decreasing the value of γ or ρ from the best-fit value
derived from the actual dataset, and using that value to calculate risk of readmission for
each simulated datapoint, will inflate or deflate the overall risk of readmission in the
simulated dataset relative to that in the true data. To adjust for this we arrived empirically
at a formula for adjusting β0 as a piecewise linear function of γ and ρ to keep the overall
simulated readmission risk within 10% of the overall readmission risk in the original
data.

Tools
Data analysis was conducted using the R language and environment for statistical
computing version 3.0.3 (39) and SAS software version 9.4 (40). The R packages foreign
(41), ggplot2 (42), Hmisc (43), lmtest (44), MKmisc (45), and rms (46) were used as
well. The SAS code to calculate Gagne scores was that from the Brigham & Women’s
Hospital Division of Pharmacoepidemiology and Pharmacoeconomics (47).
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CHAPTER 3
RESULTS

Data cleaning
We found no missing or out-of-range values in the dataset. The primary key (admission
ID) was unique in the dataset.

Baseline and summary values
A total of 2,764 CHF discharges were included in the study, 26% (716) in the preintervention phase and 74% (2048) in the intervention phase. Of the total, 21.2% (586)
were readmitted; of those in the pre-intervention phase 21.8% (156) and of those in the
intervention phase 21.0% (430) were readmitted (Table 2).
Risk of readmission, aggregated by calendar month, varied from 7.1% to 46.4%, with an
interquartile range of 16.7% – 22.9%, and with no evident trend or pattern (Table 3,
Figure 2, Figure 3, Figure 4).
A total of 2,114 distinct patients are represented through the three study phases. This
patient pool is large enough that we may regard observations as independent: the
admission of several dozen patients in a month (the maximum observed was 83, median
56) does not appreciably affect the size or characteristics of the population still available
for admission.
Patient characteristics at discharge for discharges in the pre- and post-intervention
populations showed statistically significant differences (at α = 0.05) in many
demographic and medical measures (Table 4,Table 5). We tested differences between the
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pre-intervention and post-intervention groups along continuous variables using the MannWhitney-Wilcoxon test, and differences along categorical variables using Fisher’s exact
test.

Time-series analysis
A correlogram of monthly proportions of readmission revealed no autocorrelation, with
only small and random deviations from zero for autocorrelation at lags up to 24 months
(Figure 5). The Durbin-Watson test indicated no autocorrelation for lag up to 4 months
(Table 6). The lack of autocorrelation at lag = 12 indicated no seasonal effects on
proportion of readmission, as did the lack of autocorrelation at lag = 4 for values
aggregated by quarter (September – November, December – February, March – May,
June – August) (Figure 6). We therefore did not investigate ARIMA analysis, and did not
adjust for seasonality in risk of readmission.

Non-adjusted regression model
Modeling risk of readmission as a function of time, the pre/post division, and their
interaction, we found no statistically significant evidence (at α = 0.05) that any of the
three predictors had an odds ratio (OR) ≠ 1 (Table 7). The significance of the model as a
whole gave a likelihood-ratio test value of p = 0.846, indicating that we cannot reject, at α
= 0.05, the null hypothesis that the model incorporating these predictors is no better than
the naïve model.
Overall, we concluded that there was no strong evidence that linearity of log-odds in the
predictors was an inappropriate form for modeling the response. The Hosmer-Lemeshow
"! statistic is far from statistically significant at α = 0.05 for any group size tested (Table
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8). The le Cessie-van Houwelingen-Copas-Hosmer global goodness of fit p value is 0.030
(Table 8), but in an unpredictive model, such as this one, this test statistic can be greatly
inflated (46). The Pearson residuals for this model aggregated by month give p = 0.210
(Table 8) and the Pearson residuals are normally distributed (Figure 7), as we would
expect for an appropriate model.
Examining risk of readmission, aggregated by month, as a linear function of the only
continuous predictor, time, we did not see any pattern in the data indicating that a
transform of the outcome would be more appropriate as the outcome in a logistic
regression model (Figure 8, Figure 9, Figure 10).
Combining these, we find no evidence that a logistic regression model with risk of
readmission as the outcome is an inappropriate model. However, within this framework,
the unadjusted model finds no association between the change in protocol and the risk of
readmission, or between the change in protocol and a change in the trend in risk of
readmission.
We also tested separately for a change in baseline risk following the change in protocol,
and for presence of a secular trend in risk of readmission. Testing simply for an
association between pre- versus post-implementation and risk of readmission, we again
could not reject the null hypothesis of OR = 1 (p = 0.656) (Table 9). As well, we could
not find evidence for any secular trend in risk of readmission (p = 0.750) (Table 10).
(Had any of these been significant, the issue of adjustment for multiple comparisons
would have been relevant.)
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Complete regression model
Building our best regression model using the procedure described above, we arrived at a
model incorporating age, sex, race/ethnicity, medical cost payor, and Gagne score as
predictors of risk of readmission, as well as the predictors of interest — time, i, and
time*i (Table 11).
All predictors were highly statistically significant in this model, with the exception of the
predictors of interest. We found no statistically significant evidence at α =0.05 that any of
time, i, or time*i had an OR ≠ 1. The significance of the model as a whole gave a
likelihood-ratio test value of p < 0.0001, indicating that we can reject, at α = 0.05, the
null hypothesis that the model including these predictors is no better than the naïve
model.
The statistical non-significance of the predictors of interest is not due to inflated variance
in the estimate for any of the coefficients of interest, caused by collinearity with any of
the other predictors in the model. None of the categorical covariates in this model is
associated with i (Table 5); age and Gagne score are associated with i (Table 4), but
eliminating either or both of age and Gagne score as predictors did not materially affect
the significance of the predictors of interest in the resulting models. None of the
covariates in this model is associated with time at α = 0.05 (Table 12, Table 13); only
race/ethnicity is at all associated with time (p = 0.070) but a model omitting
race/ethnicity still showed no statistical significance for the predictors of interest.
The model including these covariates shows good fit by all measures we employed. The
"! statistic is far from statistically significant at α = 0.05 for any group size tested, and the
le Cessie-van Houwelingen-Copas-Hosmer global goodness of fit p value is 0.894 (Table
27

14). Overall, this is a well-fit logistic regression model, but one which shows no
statistical significance for the predictors of interest.
As with the unadjusted regression model, we also tested separately for a change in
baseline risk following the change in protocol, and for presence of a secular trend in risk
of readmission. For each question we built a regression model as described above, and in
each case we arrived at a model including the predictors age, sex, race/ethnicity, medical
cost payor, and Gagne score in addition to the predictor of interest (Table 15, Table 16).
As with the unadjusted regression models, we could not reject the null hypothesis of no
change in baseline risk following the change in protocol (p = 0.392) or the null
hypothesis of no secular trend in risk of readmission (p = 0.433).

Statistical power
As expected, simulated study power to detect a change in baseline risk following the
change in protocol (ORγ ≠ 1) increased with simulated γ further from zero, and power to
detect a change in the trend of risk following the change in protocol (ORρ ≠ 1) increased
with simulated ρ further from zero (Table 17, Table 18, Table 19). (The two effects were
not entirely orthogonal, but the interaction does not have any clear interpretation, or may
be meaningless, due to the dependence of β0 on both γ and ρ in the regression equation
used to simulate the data.)
Power to detect ORγ ≠ 1 was 86% for an ORγ of 0.5 (at ORρ = 1; power values covered
the range from 73% to 88% for the range of ORρ values 0.94 – 1.06). Power was 75% to
detect an ORγ of 2.0 (again, at ORρ = 1; power was 50% at ORρ = 1.06, and 85% at ORρ
= 0.94). However, this power fell rapidly for values of ORγ closer to 1: power was 58% to
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detect ORγ = 0.6 and only 33% for ORγ = 1.5 (both at ORρ = 1). For the strongest effects,
power was 98% to detect ORγ = 0.4, but still only 90% for ORγ = 2.5 (both at ORρ = 1).
As the effect of a covariate on the risk of the outcome depends upon the values of the
other covariates in a logistic regression model, there is no single mapping from these
odds ratios to effects on risk of readmission. To get an indication of the magnitude of the
effects of a given OR, however, we can examine a predicted risk as calculated over the
population studied: to do this, we apply our regression model (that in Table 11) with the
given counterfactual γ and all other coefficients unchanged, to predict risks of
readmission for all actual discharges (datapoints) observed.
Doing so, an ORγ of 0.5 results in an overall predicted risk of readmission of 0.11 during
the implementation phase, in contrast to the observed risk of 0.21 during that phase (and
risk of 0.22 observed during the pre-implementation phase). An ORγ of 0.6 results in an
overall predicted risk of readmission of 0.13 during the implementation phase; and at the
other extreme, ORγ values of 2.0 and 1.5 result in overall predicted risks of readmission
of 0.33 and 0.27 during the implementation phase.
The power to detect ORρ ≠ 1 was 81% for an ORρ of 0.96 (at ORγ = 1; power values
covered the range from 74% to 85% for the range of ORγ values 0. 4 – 2.5). Power was
also 81% for an ORρ of 1.05 (at ORγ = 1; power varied widely, covering the range from
65% for ORγ = 2.5 to 93% for ORγ = 0.4). As with power to detect γ, power to detect ρ
fell off quickly: power was 56% to detect ORρ = 0.97 and 66% to detect ORρ = 1.04. At
the most extreme values simulated, power was 99% to detect ORρ = 0.94 and 92% to
detect ORρ = 1.06 (at ORγ = 1). (For scale, recall that the coefficient ρ is for trend in log-
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odds of readmission by month, so ORρ = 0.96 indicates an odds ratio of 0.61 for a year’s
difference in discharge dates.)
As with γ, we can estimate what the effect of a counterfactual ρ would be on the
population studied. As ρ affects the effect of time on risk of readmission, we cannot
express the effect of a given ρ as an overall risk of readmission. Rather, we can examine
the effect of a counterfactual ρ on the risk of readmission in each month of the
intervention phase, as against the risk, in that month, as predicted by the best regression
model. (Recall that the best regression model gave a point estimate of ρ = 0.015, but with
a p value of 0.312, so we did not conclude that ρ was significantly different nonzero at α
= 0.05.) In particular, we can compare the predicted risk of readmission in the first month
of the intervention phase with that in the last month of the intervention phase to see the
most extreme effects of a counterfactual ρ.
Also note that to examine the effects of a counterfactual ρ, we will apply the predictive
model for that ρ, and the month of interest, to the entire sample, not to the sample in that
month. This will eliminate the effects of random variation in the covariates among
months.
The expected risk of readmission by month of study (as predicted by the best regression
model, that in Table 11, applied to all discharges in the pre- and post-intervention phases)
decreases slightly over time in the intervention phase, more than offset by a slightly
increasing risk of readmission over time in the intervention phase (with neither effect
significantly nonzero at α = 0.05). In particular, the expected risk of readmission is 0.204
in the first month of the intervention phase (study month 29) and 0.213 in the last month
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of the intervention phase (study month 59). These values are the basis for comparing
predicted risks of readmission by month resulting from various simulated values of ρ.
Projecting in this way, ORρ = 0.94 results in an overall predicted risk of readmission of
0.19 in month 29, and a minuscule 0.02 in month 59. At an ORρ just below one, ORρ =
0.99 results in an overall predicted risk of readmission of 0.20 in month 29, and a stillsmall 0.11 in month 59. At the other extreme, ORρ = 1.06 results in an overall predicted
risk of readmission of 0.21 in month 29, and a huge 0.50 in month 59. At an ORρ just
above one, ORρ = 1.01 results in an overall predicted risk of readmission of 0.20 in
month 29, and 0.19 in month 59 — at values of ρ close to this, the secular trend in risk
and the change in trend due to the interruption roughly cancel each other.
Summarizing these many projections, it seems our retrospective power is small. A change
in baseline risk of readmission, in a population of like this one, from 0.22 in the preintervention phase to 0.13 in the intervention phase, would be a very substantial realworld effect; but our simulated power to detect this never rises as high even as 65%
(Table 18). Power is similarly low to detect what would be substantial effects of a change
in trend.
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CHAPTER 4
DISCUSSION
Our results indicate no statistically significant relation between introduction of the
modified CHF care protocol and either the rate of all-cause 30-day readmission or the
trend in that rate. This result does not support most previous findings, which show an
association between an improved care protocol and reduction in readmission rate. We
believe that limitations of the study may have biased results towards the null, but that the
total effect of any such effects was small.

Study limitations
We find essentially no possibility for misclassification of exposure. We also believe that
inaccurate assessment of CHF status was unlikely. Quan et al. evaluated the use of ICD-9
codes in administrative data, and found ICD-9 codes to have sensitivity of 71.6%, and
specificity of 99.3% in detecting CHF when compared to a gold standard of diagnosis
from chart review (32). The high specificity indicates that we did not include any
appreciable proportion of non-CHF patients in our study. The low sensitivity does not
apply to our situation, as Quan et al. were assessing detection of any of the conditions
present in a patient — they found a 28% chance that a patient with CHF as one of their
health conditions would not have that recorded as an ICD-9 code. For inclusion in our
source population, however, a patient would need to have CHF severe enough at
admission that it should be the primary diagnosis; we believe that almost no CHF this
severe would not be coded. The final possibility for misclassification of exposure lies in
the possibility of a patient with several health conditions, including CHF, being coded as
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a CHF admission, and placed on the CHF ward, when in fact that admission was due to
another health condition — pneumonia, for instance. This situation might bias results in
either direction, in the unlikely case that the intervention were either more or less
effective in these patients than in the intended population, but there is no reason to
believe that these unlikely miscategorizations occurred more frequently in either phase of
the study.
Selection bias may have occurred due to our inclusion in the source population of only
patients discharged from the CHF ward. If that ward tended to be fuller during one of the
study phases, and if — as seems likely — more severe patients tended to get the beds
available on that ward, then readmission could have been more likely during the phase
with higher utilization of the CHF ward. As the population of the catchment area did not
change appreciably over the course of the study, we believe this potential bias, which
could have biased results either towards or away from the null, was small.
Bias towards the null could have resulted from misclassification of the care provided
(essentially, ours was an intention-to-treat analysis). First, even prior to the ramp-up
phase, some practitioners could have provided aspects of care under the new protocol.
We believe the scope for bias here is minimal as most aspects of the new protocol
resulted from changes in hospital policies that an individual care provider could not have
implemented. More appreciably, provider adherence to the new protocol could have been
lax even during the implementation phase (incomplete attendance at multidisciplinary
meetings or rounds suggest themselves). We believe that any change to care will be
subject to organizational inertia, and that any change requiring additional provider time
or effort will necessarily be difficult; therefore, although incomplete adherence would
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have been limited by enforcement of hospital protocols, this effect could have biased our
results towards the null.
The only plausible inaccurate ascertainment of readmission would occur if a patient were
readmitted to a hospital other than Baystate Medical Center. However, Baystate Medical
Center was the only tertiary care facility in the region throughout the study, and we
estimate that few CHF patients would choose to change care providers for a serious
health condition. As well, the brief 30-day window for readmissions reduces the
possibility that patients would move out of the catchment area in that time. Thus, this
effect would have been extremely small.
The major weakness of an interrupted time-series analysis is in comparing exposed and
unexposed groups that were recruited and observed during different time spans. Any
change over time affecting the population included in the study and associated with the
outcome can be a source of confounding and bias results either towards or away from the
null. We minimized such effects via both study design and analysis. The study design
kept the exposed and unexposed groups as similar as possible, as both the exposed and
unexposed were drawn from a population that did not change appreciably between the
unexposed and exposed phases: During the study period, the population of Springfield,
MA, did not change appreciably in SES factors or age profile; no area medical centers
opened or closed to change the catchment area for Baystate Medical Center; and the
inclusion criteria (ICD-9 codes) were constant as well. Interrupted time series analysis
adjusted for the effect of any constantly-varying trends across time, and the logistic
regression model for changes in any of the covariates included in the model. Any residual
confounding could have biased the results in either direction, and we believe the
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mitigating effects of both our study design and analysis will have resulted in minimal
levels of any such effect.
Thus, we cannot conclude that study limitations biased our results appreciably towards
the null; and therefore the results of this study should be regarded as indicating a true lack
of association under these study conditions between the modified care protocol and rate
of readmission.

Care protocol
We believe there is a substantial possibility that the disparity between the results of this
study and those of most previous studies is due to the difference between the care
protocols implemented. Of the eight protocols surveyed, two included the option of home
visits and six included mandatory home visits as part of the improved protocol. Home
visits greatly reduce the rate of noncompliance with followup care, allow a professional
to evaluate any negative trends in patient health before they become severe enough to
require patient-initiated care-seeking, and allow that professional to evaluate the
adequacy of the patient’s in-home care. These effects may be major factors in reducing
rates of readmission, but home visits are not part of the protocol implemented in this
study.

Effect size and direction
The small effect sizes found in this study are also worth noting. Even were the measured
effects statistically significant, they indicate an OR of 1.08 for risk of readmission in the
post-implementation versus the pre-implementation phase, and a similarly small OR for
the change in trend (Table 11). The OR of 1.08 results in an overall predicted risk ratio
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(risk ratio as applied to the entire population studied) of 1.065 for risk of readmission in
the post-implementation versus the pre-implementation phase. This ratio also indicates,
were we to consider it either statistically significant or clinically meaningful, an increased
risk under the new protocol.

Post hoc statistical power
The statistical power arrived at by our simulation is very low, even for high simulated
values of γ (the coefficient for a post-implementation change in baseline), and for high
simulated values of ρ (the coefficient for a post-implementation change in trend) (Table
17 –Table 19). It is tempting, then, to regard our null results as only very poor evidence
against the alternative hypothesis of an effect associated with the change in protocol. If
the observed power — the power of an experiment of this type, calculated post hoc from
the observed results — were high, we could interpret this as a high probability of
rejecting the null hypothesis if it were in fact false; and thus might regard a statistically
non-significant result as providing evidence for the null hypothesis. Conversely, in our
case, we might regard our results as adding very little support to the null hypothesis.
However, as Hoenig and Heisey show (48), observed power is a monotonic function of
the p value, so all the information that can be drawn from the estimated parameters is
already present in their p values. Worse, Hoenig and Heisey show that for two otherwiseidentical studies with the same outcome, the study with the higher observed power will
also be that with the higher p value: if higher observed power is to be interpreted as
evidence in favor of the null hypothesis, then higher p values must be so interpreted as
well. In this study, then, we cannot interpret our low observed power (classically arrived
at by calculation, here by simulation) as indicating that we can dismiss our null results.
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Having rejected such an inappropriate interpretation, the post hoc power simulation still
provides useful results for further research: in populations similar to this one (in
distribution and correlation of covariates), we know what power can be expected to detect
what possible values for γ and ρ, and a slight modification of our procedure can estimate
the power for other sample sizes as well.

Other results
We find it interesting that Gagne score is such a statistically significant predictor of
outcome. As well, the effects of the Gagne score seem to be clinically significant: With
an odds ratio of 1.09 for each one point increase in Gagne score, the odds ratio for an
increase over the interquartile range — 4 points, from 3 to 7 — is 1.42. The OR of 1.42
for a 4-point increase results in an overall predicted risk ratio (risk ratio as applied to the
entire population studied) of 1.31, a change from 18% to 24% in risk of readmission.
This study was not intended to test the validity of an association between Gagne score
and risk of readmission, and no significance values have been adjusted for multiple
comparisons. But as Gagne score is easily computed, it could be a useful tool in assessing
which patients most need extra in-hospital or followup care, and we suggest that this
association merits further study.

Generalizability
We would not hesitate to generalize these results to the populations served by most other
U.S. major medical centers. Baystate Medical Center serves an ethnically and
socioeconomically diverse population, and we have no reason to believe that populations
composed of other racial and ethnic groups, more rural populations, or populations from
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the central or western U.S. would not react to CHF care as the study population did. We
also believe, due to similarities in the distribution and covariance structure of predictors,
that the results of our power simulation would apply to studies in these populations.
We would not want to generalize to settings in the less-developed world where the
standard of care is very different from that in this study. The unexposed condition in such
a setting would not resemble the unexposed condition in this study, and it is not clear
what the exposed condition of care under the new protocol would mean when starting
from such a different baseline. We would not even want to generalize to settings in
Canada or Western Europe, where standards for followup and continuity of care differ
appreciably from those in the U.S.
This leads in to the greatest limitation to generalizability, the very specificity of the
interventions implemented. The literature on changes to CHF care protocols describes
combinations of interventions as diverse as: cross-disciplinary caregiver consultation;
geographic centralization of CHF patients; aggressive medication use; medication
reconciliation; post-discharge telephone followup; dietary consultation; home RN visits;
home dietician visits; 24-hour post-discharge help line; home teaching sessions; and
advanced-care nurse case management. Of the many combinations of many possible
interventions, we would feel comfortable generalizing these results only to interventions
whose core elements were similar to the core elements implemented in this protocol, and
— as mentioned above — only in settings where the baseline of care was similar to that
in this study.
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Conclusion
These results indicate no statistically significant association (at α = 0.05) between
introduction of the new care protocol and either the baseline risk of 30-day all-cause
readmission or the trend in that risk. We believe that this is a true null result, and cannot
adequately be explained as a result of weaknesses in the study. It is hard to meaningfully
compare these results to others reported in the literature due to the heterogeneity of
interventions studied in attempts to reduce readmission rates.
For further study, we note that all-cause readmission is a noisy measure, including
readmissions due to causes entirely independent of CHF care (and thus biasing results
towards the null). More specific outcomes — particularly, readmissions due to CHF, and
readmissions due to cardiovascular disease in general — may better measure the effects
of a CHF care protocol. We suggest that studies including those outcomes as well as allcause readmission will be informative.
As well, as new CHF care protocols are implemented, the effectiveness of such measures
should be tested; we believe that interrupted time-series analysis with adjustment via
multiple logistic regression, as described here, will be appropriate and effective.
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CHAPTER 5
TABLES & FIGURES

Tables
Table 1: Classification of study variables
Description
Exposure

Type

Protocol at discharge

dichotomous

Time (month of study)

continuous

Outcome
readmission within 30 days, all causes

dichotomous

Covariates
Age at discharge (years)

continuous

Sex

dichotomous

Race/Ethnicity
white
black
Hispanic
other/unknown
Medical charge payor
commercial/HMO
Medicare
Medicaid
other
Length of hospital stay (days)

categorical
(with indicator variables for regression)

Length of hospital stay
short
medium
long
Primary diagnosis
(25 distinct ICD-9 codes represented)
Primary diagnosis, binned
(four categories)
Secondary diagnoses at discharge

categorical
(with indicator variables for regression)

Gagne comorbidity score
Discharge disposition
against medical advice
home, self care
home, visiting nurse assistance
hospice
skilled nursing/rehabilitation facility
transfer

categorical
(with indicator variables for regression)

continuous

categorical
categorical
(with indicator variables for regression)
Multiple secondary diagnoses present per discharge; link via foreign
key to table of secondary diagnoses.
continuous
categorical
(with indicator variables for regression)
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Table 2: Association between outcome and exposure phase

Readmissions

Overall
N = 2764

Pre-intervention phase
n = 716

Intervention phase
n = 2048

21.2% (586)

21.8% (156)

21.0% (430)

Table 3: Risk of readmission by calendar month
minimum

7.1%

1st quartile

16.7%

median

21.1%

Mean

21.2%

3rd quartile

22.9%

maximum

46.4%

Table 4: Associations between continuous covariates and exposure phase

Characteristic

Overall
N = 2764

Pre-intervention
phase
n = 716

Intervention
phase
n = 2048

Age, years† (median)

76

75

77

0.015

Length of hospital stay, days (median)

5

4

5

0.140

Gagne score (mean)

5.14

4.75

5.27

* Mann-Whitney-Wilcoxon test for significance
† Ages ≥ 90 recorded as 90
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p*

< 0.0001

Table 5: Associations between categorical covariates and exposure phase

Characteristic

Overall
N = 2764

Pre-intervention
phase
n = 716

Intervention
phase
n = 2048

50.0% (1383)
50.0% (1381)

48.5% (347)
51.5% (369)

50.6% (1036)
49.4% (1012)

73.6% (2035)
10.9% (301)
14.1% (389)
1.4% (39)

74.3% (532)
12.2% (87)
12% (86)
1.5% (11)

73.4% (1503)
10.4% (214)
14.8% (303)
1.4% (28)

16.2% (449)
5.6% (154)
76.9% (2126)
1.3% (35)

15.1% (108)
5.9% (42)
77.5% (555)
1.5% (11)

16.7% (341)
5.5% (112)
76.7% (1571)
1.2% (24)

0.9% (24)
3.8% (105)
13.3% (368)

3.1% (22)
5.4% (39)
7.3% (52)

0.1% (2)
3.2% (66)
15.4% (316)

82.0% (2267)

84.2% (603)

81.2% (1664)

0.8% (21)
29.2% (807)
45.6% (1261)
2.0% (55)
22.2% (614)
0.2% (6)

1% (7)
38.7% (277)
39% (279)
1.4% (10)
19.8% (142)
0.1% (1)

0.7% (14)
25.9% (530)
47.9% (982)
2.2% (45)
23% (472)
0.2% (5)

17.5% (483)
66.1% (1826)
16.5% (455)

19.1% (137)
67.3% (482)
13.5% (97)

16.9% (346)
65.6% (1344)
17.5% (358)

Sex
female
male
Race/ethnicity
white
black
Hispanic
other/unknown
Medical charge payor
commercial insurance/HMO
Medicaid
Medicare
other
Primary diagnosis
398.x Other rheumatic heart disease
402.x Hypertensive heart disease
404.x Hypertensive heart and
chronic kidney disease
428.x Heart failure
Discharge disposition
against medical advice
home, self care
home, visiting nurse assistance
hospice
skilled nursing/rehabilitation facility
transfer
Length of stay
≤ 2 days)
[3, 8] days
≥ 9 days

p*
0.340

0.202

0.643

< 0.0001

< 0.0001

0.032

* Fisher’s exact test
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Table 6: Durbin-Watson test for autocorrelation, risk of readmission by month
Order

p

1

positive
autocorrelation
0.254

negative
autocorrelation
0.746

2

0.523

0.477

3

0.179

0.820

4

0.256

0.744

Table 7: Unadjusted logistic regression model for association of time, interruption, and
interaction time*interruption with log-odds of readmission
Model

p*

Change in baseline and trend
Predictor

0.846
odds ratio

coefficient

95% CI

time (month of study, centered)

0.99

-0.009

-0.036, 0.018

0.508

post implementation of protocol (i)

1.05

0.049

-0.445, 0.554

0.847

time * i

1.01

0.012

-0.018, 0.040

0.437

* Likelihood-ratio test compared to naïve (intercept-only) model, χ2 on 3 df.
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p

Table 8: Goodness-of-fit measures for unadjusted logistic regression model for
association of time, interruption, and interaction time*interruption with log-odds of
readmission
Hosmer-Lemeshow
"! statistic*
1.69

p
0.793

8

1.77

0.940

10

4.96

0.762

12

8.45

0.585

14

14.04

0.298

20

14.61

0.689

number of groups
6

le Cessie-van Houwelingen-Copas-Hosmer global goodness of fit
! statistic
-2.18

p
0.030

X2 statistic†
-2.18

p
0.210

Pearson residuals aggregated by month

* χ2 on (number of groups – 2) df
† χ2 on 49 df.

Table 9: Unadjusted logistic regression model for association of interruption with logodds of readmission
Model
Change in baseline
Predictor

odds ratio

coefficient

95% CI

p

0.95

-0.047

-0.252, 0.162

0.656

post implementation of protocol (i)
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Table 10: Unadjusted logistic regression model for association of time with log-odds of
readmission
Model
Secular trend
Predictor

odds ratio

coefficient

95% CI

p

1.00

-0.001

-0.007, 0.005

0.750

Time

Table 11: Adjusted logistic regression model for association of time and interruption with
log-odds of readmission
Model

p*

Change in baseline and trend, adjusted for covariates
Predictor

< 0.0001
odds ratio

coefficient

95% CI

p

post implementation of protocol (i)

1.08

0.080

-0.42, 0.591

0.755

time (month of study, centered)

0.99

-0.013

-0.041, 0.014

0.333

time * i

1.02

0.015

-0.015, 0.045

0.313

age (years)

0.99

-0.013

-0.021, -0.005

0.002

sex
female
male

reference
0.80

-0.225

-0.414, -0.036

0.020

race/ethnicity
white
black
Hispanic
other/unknown

reference
1.00
1.47
1.42

-0.001
0.384
0.354

-0.322, 0.309
0.112, 0.651
-0.429, 1.055

0.994
0.005
0.345

medical charge payor
commercial insurance/HMO
Medicaid
Medicare
other

reference
1.80
1.61
0.78

0.585
0.475
-0.252

0.151, 1.013
0.185, 0.775
-1.494, 0.724

0.008
0.002
0.647

1.09

0.087

0.045, 0.129

< 0.0001

Gagne score

* Likelihood-ratio test compared to naïve (intercept-only) model, χ2 on 12 df.
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Table 12: Associations between continuous covariates in regression model and month of
study (omitting data from ramp-up phase)
Characteristic

Pearson’s r

Spearman’s ρ

Kendall’s τ

age

0.05

0.05

0.03

Gagne score

0.12

0.11

0.08

Table 13: Associations between categorical covariates in regression model and month of
study (omitting data from ramp-up phase)
Characteristic

p*

race/ethnicity

0.070

sex

0.462

medical charge payor

0.799

* Kruskal-Wallis rank-sum test for significance

Table 14: Goodness-of-fit measures for adjusted logistic regression model for association
of time, interruption, and interaction time*interruption with log-odds of readmission
Hosmer-Lemeshow
"! statistic*
4.83

p
0.306

8

4.76

0.575

10

1.86

0.985

12

8.35

0.595

14

6.33

0.899

20

16.89

0.530

number of groups
6

le Cessie-van Houwelingen-Copas-Hosmer global goodness of fit
! statistic
0.13
* χ2 on (number of groups – 2) df
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p
0.894

Table 15: Adjusted logistic regression model for association of interruption with log-odds
of readmission
Model

p*

Change in baseline, adjusted for covariates
Predictor

< 0.0001
odds ratio

coefficient

95% CI

p

post implementation of protocol

0.91

0.092

-0.301, 0.120

0.392

age (years)

0.99

-0.013

-0.021, -0.005

0.002

sex
female
male

reference
0.80

-0.222

-0.412, -0.034

0.021

race/ethnicity
white
black
Hispanic
other/unknown

reference
1.00
1.46
1.41

0.004
0.377
0.343

-0.325, 0.306
0.106, 0.644
-0.438, 1.043

0.981
0.006
0.358

medical charge payor
commercial insurance/HMO
Medicaid
Medicare
Other

reference
1.80
1.60
0.76

0.589
0.470
-0.274

0.155, 1.017
0.180, 0.769
-1.516, 0.702

0.007
0.002
0.619

1.09

0.086

0.044, 0.127

< 0.0001

Gagne score
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Table 16: Adjusted logistic regression model for association of time with log-odds of
readmission
Model

p*

Secular trend, adjusted for covariates
Predictor

< 0.0001
odds ratio

coefficient

95% CI

p

time (month of study, centered)

1.00

0.002

-0.008, 0.004

0.433

age (years)

0.99

0.013

-0.021, -0.005

0.002

sex
female
male

reference
0.80

0.222

-0.411, -0.033

0.021

race/ethnicity
white
black
Hispanic
other/unknown

reference
1.00
1.46
1.41

-0.004
0.378
0.345

-0.325, 0.305
0.107, 0.646
-0.437, 1.045

0.979
0.006
0.356

medical charge payor
commercial insurance/HMO
Medicaid
Medicare
other

reference
1.80
1.60
0.76

0.589
0.471
-0.270

0.155, 1.017
0.181, 0.770
-1.512, 0.705

0.007
0.002
0.624

1.09

0.086

0.044, 0.128

< 0.0001

Gagne score

* Likelihood-ratio test compared to naïve (intercept-only) model, χ2 on 10 df.
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Table 17: Study power (by simulation)
γ

ORγ

ρ

ORρ

-0.92

0.4

-0.69

0.5

-0.51

0.6

-0.36

0.7

-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058
-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058
-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058
-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058

0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06
0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06
0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06
0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06

Power to detect (%)
ORγ ≠ 1 ORρ ≠ 1
98
98
98
98
98
98
98
97
96
94
94
96
87
84
85
84
85
88
85
81
78
75
77
73
62
64
58
64
58
60
60
53
52
52
47
49
34
35
35
34
32
34
33
31
32
27
25
23

99
96
82
56
30
13
10
29
55
76
93
97
99
95
80
56
32
12
11
31
55
77
90
97
99
95
82
60
29
14
9
28
53
79
88
95
99
96
83
60
29
12
12
25
47
74
84
95
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γ

ORγ

ρ

ORρ

-0.22

0.8

0.18

1.2

0.26

1.3

0.41

1.5

-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058
-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058
-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058
-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058

0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06
0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06
0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06
0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06

Power to detect (%)
ORγ ≠ 1 ORρ ≠ 1
15
18
17
19
17
16
15
15
16
14
13
14
13
11
14
11
11
16
9
10
8
6
10
10
21
24
22
19
15
16
13
17
15
14
13
13
39
40
39
40
36
36
30
34
29
26
27
23

98
95
85
56
30
11
9
27
50
68
88
94
99
97
81
56
27
11
9
24
42
64
80
88
99
93
82
58
27
11
9
27
42
62
83
88
100
94
81
55
28
10
7
25
45
61
74
86
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γ

ORγ

ρ

ORρ

0.69

2.0

0.92

2.5

-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058
-0.062
-0.051
-0.041
-0.030
-0.020
-0.010
0.010
0.020
0.030
0.039
0.049
0.058

0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06
0.94
0.95
0.96
0.97
0.98
0.99
1.01
1.02
1.03
1.04
1.05
1.06

Power to detect (%)
ORγ ≠ 1 ORρ ≠ 1
85
80
80
79
76
74
69
63
62
61
54
50
95
95
95
95
95
93
91
88
87
81
78
73

99
94
77
49
25
8
7
20
36
57
67
78
99
90
74
43
27
11
10
19
33
52
65
75
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Table 18: Study power (by simulation) to detect ORγ ≠ 1

Table 19: Study power (by simulation) to detect ORρ ≠ 1
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Figures

Figure 2: Probability of readmission by month of study, with weighted moving average

Figure 3: Logit(probability of readmission) by month of study, with weighted moving
average
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Figure 4: Histogram of probability of readmission, by month, with kernel density

Figure 5: Autocorrelation of probability of readmission by calendar month

autocorrelation function

Autocorrelation, p(readmission) by month

lag (months)
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Figure 6: Autocorrelation of probability of readmission by quarter

autocorrelation function

Autocorrelation, p(readmission) by quarter

lag (quarters)

Figure 7: Q-Q normal plot of Pearson residuals, for readmissions aggregated by calendar
month, with regression model including time, i, and time*i as predictors
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Figure 8: Logit(probability of readmission) by month of study, pre-implementation phase,
with loess best fit and best-fit line

Figure 9: Logit(probability of readmission) by month of study, post-implementation
phase, with loess best fit and best-fit line
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Figure 10: Logit(probability of readmission) by month of study, all study months, with
loess best fit and best-fit line
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APPENDIX:
ICD-9 DIAGNOSIS CODES USED TO DETERMINE CHF DISCHARGE
DIAGNOSIS
Description

Code

Heart failure

428.x

Congestive heart failure, unspecified

428.0

Left heart failure

428.1

Systolic heart failure (.2x, x = 0 – 3)

428.2

Diastolic heart failure (.3x, x = 0 – 3)

428.3

Combined systolic and diastolic heart failure (.4x, x = 0 – 3)

428.4

Rheumatic heart failure

398.91

Malignant Hypertensive heart disease with HF

402.01

Benign Hypertensive heart disease with HF

402.11

Unspecified Hypertensive heart disease with HF

402.91

Malignant Hypertensive heart and chronic kidney disease stage I–IV, or unspecified with HF

404.01

Malignant Hypertensive heart and chronic kidney disease stage V or ESRD with HF

404.03

Benign Hypertensive heart and chronic kidney disease stage I–IV, or unspecified with HF

404.11

Benign Hypertensive heart and chronic kidney disease stage V or ESRD with HF

404.13

Unspecified Hypertensive heart and chronic kidney disease stage I - IV, or unspecified with HF

404.91

Unspecified Hypertensive heart and chronic kidney disease stage V or ESRD with HF

404.93

Cardiomegaly

429.3
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